Last Updated: September 27, 2026
A 340B carve-out removes a defined set of drugs from a covered entity's contract pharmacy arrangement so those claims no longer fill under 340B pricing, and the 340B carve-out conversation almost always starts with the same discovery. In programs we run, the conversation almost always starts with the same discovery: a whole drug class is quietly losing money.
Here's what most statements hide:
A 340B contract pharmacy net-per-claim analysis calculates what the covered entity actually keeps per claim after the ceiling price, dispensing fee, TPA fee, and any withhold. The output is a true number per claim by drug class, not a blended total, and the arithmetic is where carve-out decisions get made.
Build one row per claim, one column per money field. The formula is simple; the discipline is not skipping fields.
What to verify on every line:
Read the TPA statement on both a cash and an accrual basis before concluding a class is negative.
| View | What It Shows | What It Hides |
|---|---|---|
| Cash basis | What actually hit the bank this month | Trailing insurer A/R not yet collected |
| Accrual basis | Margin earned on claims adjudicated this month | Cash still sitting in the pharmacy's account |
Group claims by drug class, then calculate net per claim for each. HIV antiretrovirals usually hold positive; non-HIV generics frequently do not.
| Drug Class | Typical Net per Claim | Common Driver | Action |
|---|---|---|---|
| HIV antiretrovirals | Positive | Higher ceiling-to-reimbursement spread | Keep in contract pharmacy |
| Injectable PrEP | Positive | Drug plus administration billed together | Keep, watch documentation |
| Non-HIV generics | Negative to flat | Low spread, fees exceed margin | Carve out or move modality |
| Specialty brand | Varies | Manufacturer restrictions may apply | Check eligibility per drug |
HRSA's 340B program guidance and covered entity resources
Carve-in versus carve-out is a margin decision, not a philosophical one. Carve-in keeps everything in the contract pharmacy; carve-out removes specific drugs or classes; a modality change often beats both. The mistake is treating this as one decision when it is two: the Medicaid carve-in election and the commercial carve-out of specific classes.
The math is straightforward once you have class-level net. If a class nets negative on every claim, removing it stops the bleed immediately, the swing is eliminated loss per claim multiplied by claim volume, not the drug's revenue.
| Situation | Recommended Path | Why |
|---|---|---|
| Class nets clearly negative on cash and accrual | Carve out | Stop the loss per claim |
| Class nets flat but strategic | Keep, renegotiate fees | Patient access matters |
| Fees are the problem, not the drug | Move to a new modality | Virtual or replenishment models cut cost |
| Physical inventory model required | Model month by month first | Clinic may fund about a month of COGS |
| Volume high, margin thin | Reduce volume, then transition | Lets A/R collect before notice |
340B Medicaid carve-in means the covered entity chooses to use 340B drugs for its Medicaid patients. That election is independent of whether you carve out non-HIV generics at the contract pharmacy, you can do both at once.
What to verify:
Execution is where most carve-outs stall. The analysis says go, but nothing changes because no one put it in writing with the pharmacy.
340B Medicaid carve-in means the covered entity chooses to use 340B drugs for its Medicaid patients. Once made, the entity's Medicaid provider ID must appear on the HRSA Medicaid Exclusion File for every site and billing number it uses.
What to verify:
Execution is where most carve-outs stall: the analysis says go, but nothing changes because no one put it in writing with the pharmacy. Here is the workflow we use.
What You'll Need:
CDC guidance on 340B and public health program requirements
Track these monthly:
If the carve-out was the right call, margin should improve within a quarter. If it does not, the problem was never the drug class, it was the fee structure, and the next move is a modality change.
Book a free 30-minute strategy call
A carve-out removes specific drug classes, typically non-HIV generics, from your contract pharmacy arrangement so those claims no longer run through the 340B program. The pharmacy dispenses them under standard commercial or Medicaid reimbursement instead. Covered entities carve out when net-per-claim analysis shows a drug class consistently loses money after dispensing fees, TPA charges, and wholesaler acquisition costs are applied. The carve-out must be documented in writing with the pharmacy and reflected in your TPA configuration.
Generic drugs carry low 340B ceiling prices, which sounds favorable until you subtract the full cost stack. Dispensing fees, TPA per-claim charges, and wholesaler minimums often exceed the spread between the ceiling price and the reimbursement rate. Low-cost generics like metformin or lisinopril may net a few cents per claim or go negative once every fee is allocated. In our experience, reviewing net-per-claim by drug class reveals that non-HIV generics are the most common source of hidden losses at contract pharmacies.
Pull the pharmacy claim detail from your TPA and build a line-by-line margin view. For each claim, subtract the 340B ceiling price, dispensing fee, and any per-claim TPA charge from the reimbursement received. Group results by drug class: HIV antiretrovirals, non-HIV generics, specialty, and so on. Read your TPA monthly statement on both cash and accrual bases, because cash-basis ledgers can show you owing the pharmacy while accrual shows the pharmacy holding your margin in trailing insurer A/R. Review at least one full quarter before deciding.
Carving out non-HIV generics reduces 340B volume, which can affect manufacturer rebate thresholds and contract pharmacy performance guarantees. Patient access should not change since the pharmacy still dispenses the medication, just under a different reimbursement pathway. Watch your Medicaid rules: if your entity is carved in to Medicaid FFS, removing a drug class from 340B does not remove duplicate discount obligations. Document the carve-out in writing and update your TPA prescriber and drug-class configuration to prevent claims from running through the wrong pathway.
Bring us your patient acquisition, 340B program, or compliance bottleneck. We will show you what a 30-day launch looks like for your clinic — in English or Spanish, month to month, no long contract.
